
Sign up to save your podcasts
Or


Today's episode features the CEO of Tome Biosciences, Rahul Kakkar, alongside John Finn, CSO of Tome. They are joined by Jorge Conde, general partner at a16z Bio + Health.
Together, the three of them discuss the technology underlying Tome's work, known as PASTE, a genome editing technique. They also dive deep into how this technology could be applied to help patients, making cell therapy more accessible for more people.
Editorial note: We mistakenly identified Rahul Kakkar and John Finn as the co-founders of Tome Biosciences. In reality, Rahul serves as the CEO, and John is the CSO of Tome. The actual co-founders of Tome Biosciences are Jonathan Gootenberg and Omar Abudayyeh.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By Andreessen Horowitz, a16z Bio + Health4.6
143143 ratings
Today's episode features the CEO of Tome Biosciences, Rahul Kakkar, alongside John Finn, CSO of Tome. They are joined by Jorge Conde, general partner at a16z Bio + Health.
Together, the three of them discuss the technology underlying Tome's work, known as PASTE, a genome editing technique. They also dive deep into how this technology could be applied to help patients, making cell therapy more accessible for more people.
Editorial note: We mistakenly identified Rahul Kakkar and John Finn as the co-founders of Tome Biosciences. In reality, Rahul serves as the CEO, and John is the CSO of Tome. The actual co-founders of Tome Biosciences are Jonathan Gootenberg and Omar Abudayyeh.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

1,285 Listeners

537 Listeners

1,084 Listeners

2,343 Listeners

125 Listeners

321 Listeners

104 Listeners

86 Listeners

34 Listeners

25 Listeners

18 Listeners

161 Listeners

60 Listeners

57 Listeners

136 Listeners

141 Listeners

473 Listeners

35 Listeners